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Abstract: Laparoscopic and open liver resection have not been
compared in randomized trials. The aim of the current study was to
compare the inflammatory response after laparoscopic and open resec-
tion of colorectal liver metastases (CLM) in a randomized controlled
trial.
This was a predefined exploratory substudy within the Oslo CoMet-
study. Forty-five patients with CLM were randomized to laparoscopic
(n¼ 23) or open (n¼ 22) resection. Ethylenediaminetetraacetic acid-
plasma samples were collected preoperatively and at defined time points
during and after surgery and snap frozen at 80 oC. A total of 25
markers were examined using luminex and enzyme-linked immuno-
sorbent assay techniques: high-mobility box group 1(HMGB-1), cell-
free DNA (cfDNA), cytokines, and terminal C5b-9 complement com-
plex complement activation.
Eight inflammatory markers increased significantly from baseline:
HMGB-1, cfDNA, interleukin (IL)-6, C-reactive protein, macrophage
inflammatory protein -1b, monocyte chemotactic protein -1, IL-10, and
terminal C5b-9 complement complex. Peak levels were reached at the
end of or shortly after surgery. Five markers, HMGB-1, cfDNA, IL-6, C-, PhD, Morten Wa MSc, PhD,
and Bjorn Edwin, MD, PhD
Laparoscopic resection of CLM reduced the inflammatory response
compared with open resection. The lower level of HMGB-1 is inter-
esting because of the known association with oncogenesis.
(Medicine 94(42):e1786)
Abbreviation: ASA = American Society of Anesthesiology
classification, AUC = area under the curve, bFGF = basic
fibroblast growth factor, cfDNA = cell-free DNA, CLM =
colorectal liver metastases, CONSORT = Consolidated Standards
of Reporting Trials, CRP = C-reactive protein, DAMP = damage-
associated molecular patterns, EDTA = ethylenediaminetetraacetic
acid, ELISA = enzyme-linked immunosorbent assay, ERAS =
enhanced recovery after surgery, G-CSF = granulocyte colony-
stimulating factor, GM-CMF = granulocyte macrophage colony-
stimulating factor, HMGB-1 = high-motility group box 1, IFN =
interferon, IL1-ra = interleukin-1 receptor antagonist, IP-10 =
interferon-inducible protein, MCP-1 = monocyte chemotactic
protein, MIP = macrophage inflammatory protein, PDGF-BB =
platelet-derived growth factor-BB, RANTES = regulated upon
activation T cell expressed and secreted, RCT = randomized
controlled trial, TCC = terminal C5b-9 complement complex, TNF
= tumor necrosis factor, tregs = regulatory T cells, VEGF =
vascular endothelial growth factor, Ymax = maximum value across
all time points.
INTRODUCTION
L aparoscopic liver surgery is replacing the open technique inmany centers worldwide. Comparative studies, however, are
limited because of their retrospective and nonrandomized
nature. To date, no randomized controlled trial (RCT) has been
conducted. The 2nd International Consensus Conference on
Laparoscopic Liver Resection concluded that higher quality
studies are needed to determine the role of laparoscopic liver
surgery in relation to open surgery.1
Any surgical procedure is a controlled tissue injury. Trau-
matic tissue injury leads to release of intracellular substances,
which act as endogenous triggers of the immune system, often
referred to as alarmins or damage-associated molecular patterns
(DAMP).2,3 Alarmins such as high-mobility group box 1
(HMGB-1) and circulating cell-free DNA (cfDNA) are associ-
ated to tissue trauma-induced inflammatory responses.4 Recent
studies also strongly, however, associate HMGB-1 and cfDNA
with cancer development and progression.5–7
A reduced inflammatory response has been considered an
opy compared with open surgery. A
response has been found following
olorectal surgery,8 cholecystectomy,9
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appendectomy,10 perforated ulcer repair,11 and lung resection,12
when compared with open procedures. Decreased interleukin 6
(IL-6) after laparoscopic surgery was the most consistent find-
ing in these studies. A reduced inflammatory response has also
been associated with better-preserved immune competence in
the postoperative period, which may influence both surgical
complications and tumor metastasis formation.8,12 Results from
previous studies have indicated a survival benefit of the laparo-
scopic method in patients with colorectal liver metastases
(CLM).13 A reduced inflammatory response has been discussed
as one possible explanation for this.
Animal trials have shown decreased levels of IL-6 after
laparoscopic liver resection,14 but the inflammatory response
following laparoscopic liver resection has not been described in
humans. The aim of the current study was thus to compare the
inflammatory response following laparoscopic and open liver
resection for CLM.
MATERIALS AND METHODS
Study Overview
This study was a predefined exploratory substudy of the
randomized Oslo CoMet-study.15 The end point was inflam-
matory response after open compared with laparoscopic liver
resection, assessed pre-, per- and postoperatively. The first 45
patients recruited to the Oslo CoMet-study were included.
Inclusion and operations took place between February and
October 2012 Figure 2. Because of the cost of obtaining and
analyzing the samples, it was not possible to perform this study
on the entire Oslo CoMet-study population. No power analysis
was performed as this study was piggy backed onto the main
trial. The decision of including 45 patients was thus based on
previous experience and economical limitations. The study was
approved by the Regional Committee for Health and Research
Ethics (2011/1285/REK Sør-Øst B), by the Data Protection
Official for Research at Oslo University Hospital, and the study
was registered in Clinicaltrials.gov (NCT01516710, January 19,
2012). The Consolidated Standards of Reporting Trials check-
list was used.
The Oslo CoMet-study includes all resections of less than 3
consecutive liver segments for colorectal metastases except
resections where reconstruction of vessels or bile ducts is
necessary and resections that need to be combined with abla-
tion. All surgery was performed at Oslo University Hospital,
Rikshospitalet, Oslo, Norway by 8 consultant hepato-pancreato-
biliary surgeons.
Patient Management
The patients underwent computer-generated randomiz-
ation to open (n¼ 22) or laparoscopic (n¼ 23) resection of
CLM after giving informed, written consent. Patients were
informed about the study and the surgical procedure at the
outpatient clinic, and about the operation method on the day
before surgery. One patient in each group was operated but did
not undergo liver resection. The patient in the open group was
deemed inoperable after laparotomy, when small metastases
were found in all liver segments. The patient in the laparoscopic
group had a metastasis that vanished completely after che-
motherapy, and the tumor could not be found, even after
application of a hand port for contrast-enhanced ultrasound
examination of the liver. In addition, one patient randomized to
Fretland et allaparoscopy was excluded from the study after randomization,
as his tumor was re-evaluated to be benign on the day of surgery.
He did not undergo surgery and is still cancer free.
2 | www.md-journal.comPatients followed an enhanced recovery after surgery
(ERAS) protocol when possible. In cases where patients could
not follow an enhanced recovery after surgery protocol, as in the
case of prolonged intensive care treatment, the protocol was
initiated as soon as possible. Surgical technique was at the
discretion of the operating surgeon. For open surgery, an L-
shaped, subcostal or midline incision was used. For laparo-
scopy, three 12mm trocars were used as a standard, with the
addition of trocars or hand port when necessary. For both open
and laparoscopic resections, liver parenchyma was transected
with electrosurgical instruments, mainly LigaSure1 (Covidien,
Mansfield, MA), Thunderbeat1 (Olympus, Tokyo, Japan), or
Caiman1 (B.Braun, Melsungen, Germany) sometimes assisted
by ultrasonic aspirators, mainly SonoSurg aspirator1 (Olym-
pus, Tokyo, Japan) and So¨ring aspirator1 (So¨ring, Quickborn,
Germany). Endoscopic staplers, Endo-GIA1 (Covidien, Mans-
field, MA) and Endopath1 (Ethicon, Bridgewater, NJ) were
used for dividing large vessels and sometimes for parenchyma
division. The safe surgery checklist was used.16
Collection of Samples
Whole blood samples were drawn from a central venous
line after general anesthesia was established (T1), before liver
transection (T2), 10 minutes into liver transection (T3), at end of
surgery (T4), 2 (T5), 6 (T6), and 24 hours after surgery (T7). In
total, 260 of the planned 308 samples (84.4%) were eligible for
statistical analysis. Five samples were not drawn according to
protocol. Two samples from 1 patient in the laparoscopy group
were not drawn because of personal error. The patient who
underwent laparotomy but was inoperable had no sample drawn
at T3. The patient who underwent laparoscopy but had a
vanished lesion had no samples drawn at T2 and T3. The
remaining missing data were sample exclusions as reported
by the analysis instruments.
Blood samples were drawn into vacutainer tubes contain-
ing Ethylenediaminetetraacetic acid (EDTA) and immediately
put on ice. Samples were then centrifuged at 4 -C, 1400 g for
15 minutes, and EDTA-plasma was aliquoted in triplicate to 1
mLNunc1CryoTubes1 (ThermoFischer Scientific,Waltham,
MA), and immediately frozen at 80 -C. Laboratory analyses
were performed in one batch at the Department of Immunology
at Oslo University Hospital, Rikshospitalet during March and
April 2014.
Markers of Perioperative Immune Activation
High-mobility box group 1 was analyzed by standard
enzyme-linked immunosorbent assay (ELISA) technique
according to instructions from the manufacturer (HMGB-1
ELISA Kit II, Shino-Test Corporation, Kanagawa, Japan).
Cell-free DNA was analyzed in EDTA-plasma samples
using the PicoGreen-based cfDNA-Quant kit from Trillium
diagnostics (Brewer, ME). All samples were diluted 1:5 in
PBS and analyzed according to the manufacturer’s instructions.
The fluorescent signal was measured with a Victor3TM 1420
multilabel counter (Perkin Elmer, Boston, MA) using wave-
lengths for excitation and emission at 485 nm and 530 nm,
respectively. Obtained values were related to a standard of
human placental DNA and results were given as ng/mL.
Cytokines, chemokines, and growth factors were analyzed
in plasma samples using a multiplex cytokine assay (Bio-Plex
Medicine  Volume 94, Number 42, October 2015Human Cytokine 27-Plex Panel; Bio-Rad Laboratories Inc.,
Hercules, CA) containing the following analytes: IL-1b, IL-1
receptor antagonist (IL1-ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
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stimulate tumor cell proliferation through an alteration of
tumor metabolism. In the same study, inhibition of HMGB-1
or its receptors reduced tumor growth.24 Thus, in this trial
TABLE 1. Preoperative Patient Characteristics
Laparoscopic
(n¼ 22)
Open
(n¼ 22)
ASA-classification,
mean (SD)
2.2 (0.7) 2.0 (0.6)
BPI, preoperatively,
mean (SD)
6.0 (3.5) 5.9 (3.0)
Age, mean (SD) 66.6 (10.2) 64.4 (11.6)
Body mass index,
mean (SD)
26.4 (4.7) 24.9 (3.5)
Tumor diameter,
mean (SD)
34.2 (20.4) 41.7 (33.6)IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, eotaxin, basic
fibroblast growth factor, granulocyte colony-stimulating factor,
granulocyte macrophage colony-stimulating factor, interferon-
g, interferon-inducible protein 10, monocyte chemotactic
protein, macrophage inflammatory protein (MIP)-1a, MIP-
1b, platelet-derived growth factor-BB (PDGF-BB), regulated
upon activation T cell expressed and secreted (RANTES), tumor
necrosis factor-a, and vascular endothelial growth factor. The
samples were analyzed on a Multiplex Analyser (Bio-Rad
Laboratories) according to instructions from the manufacturer.
Macrophage inflammatory protein 1-a, IL-1b, IL-12, and IL-15
could not be detected in levels above 20 pg/L, and were there-
fore excluded from further analysis. Platelet-derived growth
factor and regulated upon activation T cell expressed and
secreted were excluded for methodological reasons, as platelets
spontaneously release these after sampling unless special plate-
let preservation precautions are taken.
The terminal C5b-9 complement complex (TCC) concen-
tration was measured by an ELISA based on the mouse antihu-
man TCC antibody (clone aE11) reacting with a neoepitope
exposed in C9 when incorporated into C5b-9. The assay has
been described in detail previously.17
Total protein was measured with a colorimetric assay, and
C-reactive protein (CRP) with a particle-enhanced turbidimetric
immunoassay on the Modular p8001 (Roche, Basel, Switzer-
land) at the Department of Medical Biochemistry, Oslo
University Hospital.
To compensate for hemodilution during surgery, total protein
concentration was measured in all samples, and every analysis
result was corrected against baseline protein concentration.
Statistical Analysis
All 44 patients who underwent surgery, and thus had blood
samples drawn, were included in the statistical analysis.
The statistical analyses were performed with SPSS1 for
Mac v. 22 (IBM, Armonk, NY). For all 25 analytes, 2 measures
were calculated: the area under the curve (AUC), and the
maximum value across all time points (Ymax). The differences
between the means for the open and laparoscopic groups were
estimated with linear regression. All regression models included
an adjustment for the baseline value.
When analyzing repeated measurements of biologic sub-
stances, more than one statistical measure can be appropriate.
The ‘‘Ymax’’ analysis provides information on the peak value of
each analyzed substance, whereas the AUC provides infor-
mation on the total production of the substance during the
study period. In our experience, AUC and Ymax supplement
each other and should therefore both be reported.
In this exploratory study we performed 25 tests on the same
set of samples. We discussed whether multiple testing correc-
tions should be applied, for instance the Bonferroni test. The
analyses we performed, however, are biologically correlated, as
they are measures of inflammation. When multiple outcomes
that represent the same underlying mechanism are examined, a
Bonferroni correction would unacceptably increase the risk of
Type 2 error, thus failing to detect an effect that is present.18
Therefore, no multiple testing correction has been applied on
these results.
RESULTS
Medicine  Volume 94, Number 42, October 2015Patient Characteristics
Patient characteristics such as age, sex, body mass
index, American Society of Anesthesiology classification,
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Basingstoke Predictive Index,19 and tumor size were similar
in the laparoscopic and open surgery group (Table 1).
Inflammatory Response in the Laparoscopic
Versus the Open Group
Of the 25 inflammatory markers examined, 8 showed a
significant increase from baseline to maximum levels: HMGB-
1, cfDNA, IL-6, CRP, MIP-1b, MCP-1, IL-10, and TCC
(Tables 2 and 3). Five of these, HMGB-1, cfDNA, IL-6,
CRP, and MIP-1b, showed significantly (P< 0.05) lower levels
in the laparoscopic surgery group compared with the open
surgery group either by maximum level (Table 2), AUC
(Table 3) or both (Fig. 1, where 4 markers are shown). Three
markers did not show a significant difference between the
groups (MCP-1, IL-10, and TCC). For the other 17 markers
the surgery did not induce any significant increase from baseline
to maximum, indicating no impact of surgery.
DISCUSSION
In the current study, we found significantly lower levels of
several inflammatory markers in patients randomized to laparo-
scopic resection of CLM compared with patients randomized to
open resection. This is the first RCT to study the impact of
laparoscopic liver resection on the immune system in humans,
and thus the first attempt to find immunologic differences
between the techniques that could explain a possible survival
benefit of laparoscopy. Randomization and a consistent use of
an enhanced recovery pathway minimized bias in this study.
The low number of patients is a limitation to this study;
however, statistically significant differences could be seen
despite this. Another possible limitation is that 2 different
methods were used for comparing the groups. In our experience,
both methods, however, should be reported to completely
describe the inflammatory response.
Levels of HMGB-1 were lower in the laparoscopic group
than the open group. High-mobility group box 1 initiates
inflammation; therefore, this finding strengthens the existing
evidence that laparoscopic surgery diminishes the inflammatory
response. High-mobility group box 1 also, however, plays a role
in cancer development.20–23 Recently, HMGB-1 was found to
Inflammation After Laparoscopic Versus Open Liver ResectionASA¼American Society of Anesthesiology, BPI¼Basingstoke Pre-
dictive Index, SD¼ standard deviation.
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FIGURE 1. Levels of high-mobility box group 1, cell free DNA , interleukin 6, andmacrophage inflammatory protein 1b at T1, T2, T4, T6,
and T7 (n¼22) in each group, graph shows mean values with 95% confidence interval.
TABLE 3. Difference Between Open Liver Resection Group
and Laparoscopic Liver Resection, Measured by Area Under
the Curve
Difference in
AUC From
OLR to LLR 95% CI P Value
HMGB-1 (ng

min/mL) 1756 (3584, 73) 0.059
cfDNA (ng

min/mL) 270160 (499140, 41180) 0.022
IL-6 (pg

min/mL) 38215 (74767, 1663) 0.041
CRP (mg

min/L) – – –
MIP-1b (pg

min/mL) 27041 (51905, 2178) 0.034
MCP-1 (pg

min/mL) 14635 (30768, 1499) 0.074
TCC (AU

min/mL) 164 (704, 1034) 0.70
IL-10 (pg

min/mL) 7101 (13893, 28096) 0.68
AU¼ arbitrary units, AUC¼ area under the curve, cf-DNA¼ cell-
free DNA, CI¼ confidence interval, CRP¼C-reactive protein, HMGB-
1¼ high-mobility group box 1, IL-10¼ interleukin 10, IL-
6¼ interleukin 6, LLR¼ laparoscopic liver resection group, MCP-
1¼monocyte chemotactic protein, MIP-1b¼macrophage inflamma-
tory protein 1b, OLR¼ open liver resection group, TCC¼ terminal
complement complex.
Represents multiplication.
TABLE 2. Difference in Time Independent Maximum Levels
(Ymax) From Open Group to Laparoscopic Group
Difference in
Time-Independent
Maximum Level
(from OLR to LLR) 95% CI P Value
HMGB-1 (ng/mL) 4.6 (8.4, 0.8) 0.018
cfDNA (ng/mL) 291.4 (585.9, 3.0) 0.052
IL-6 (pg/mL) 43.9 (87.4, 0.5) 0.047
CRP (mg/L) 49.4 (94.3, 4.4) 0.032
MIP-1b (pg/mL) 57.8 (115.6, 0.02) 0.050
MCP-1 (pg/mL) 19.8 (44, 5) 0.118
TCC (AU/mL) 0.3 (1.6, 1.1) 0.710
IL-10 (pg/mL) 13.8 (46, 18) 0.390
AU¼ arbitrary units, cf-DNA¼ cell-free DNA, CI¼ confidence
interval, CRP¼C-reactive protein, HMGB-1¼ high-mobility group
box 1, IL-10¼ interleukin 10, IL-6¼ interleukin 6, LLR¼ laparoscopic
laparoscopic liver resection group, MCP-1¼monocyte chemotactic
protein, MIP-1b¼macrophage inflammatory protein 1b, OLR¼ open
open liver resection group, TCC¼ terminal complement complex,
Ymax¼ time-independent maximum level.
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Medicine  Volume 94, Number 42, October 2015 Inflammation After Laparoscopic Versus Open Liver Resectionlaparoscopy seemed to reduce not both inflammation, and levels
of a potentially oncogenic protein.
Levels of cfDNA turned out to be significantly lower in the
laparoscopic group. Cell-free DNAs are fragments of extracellu-
lar DNA detectable in plasma, and are shown to initiate an
inflammatory response together with HMGB-1 and other
damage-associated molecular patterns. Cell-free DNA is a mar-
ker of tissue damage, but concentrations also increase in cancer
patients. Therefore, cfDNA has been proposed as a biomarker
for the diagnosis, monitoring, and prognosis in cancer.7
Levels of IL-6 were lower in the laparoscopic group
compared with open. This is consistent with previous compari-
sons of open and laparoscopic surgery. Interleukin-6, an acute
phase mediator involved in B-cell stimulation, antibody pro-
duction, and further release of acute phase proteins including
CRP, is considered an indicator of the extent of surgical trauma,
and might serve as a predictor for complications. Two previous
FIGURE 2. Consolidated Standards of Reporting Trials flow diagrastudies comparing open and minimally invasive surgery found a
correlation between increased IL-6 postoperatively and a
reduced cellular immunity in the following days.8,12
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Levels of CRP and MIP-1b were also lower in the laparo-
scopic group compared with the open group. C-reactive protein
enhances the inflammatory response by complement activation
and other effects. C-reactive protein is widely used as a marker
of inflammatory response, and is also used as a prognostic
marker in hepatocellular carcinoma25 and colorectal cancer.26
Macrophage inflammatory protein-1b attracts monocytes,
natural killer cells, and regulatory T cells (Tregs) to the site
of inflammation. Inhibiting the MIP-1b-dependent attraction of
Tregs to a tumor site is associated with delayed tumor growth in
mice,27 and has been suggested as a target for treatment of
systemic colorectal cancer in humans.28
Terminal C5b-9 complement complex was just moderately
and similarly increased in both open and laparoscopic groups.
Terminal C5b-9 complement complex reflects complement
activation as the final downstream activation product. Previous
studies from our group have shown significantly increased TCC
levels after cardiopulmonary bypass, but not after thoracotomy
or open abdominal aortic aneurysm repair.29 This is consistent
with the current findings. Thus, none of the techniques seem to
www.md-journal.com | 5
activate the complement system to a degree that is measurable
in the systemic circulation.
CONCLUSIONS
In this randomized study we found a reduced inflammatory
response after laparoscopic liver resection compared with open,
represented by decreased levels of HMGB-1, cfDNA, IL-6,
CRP, and MIP-1b. In a previous study, we found that patients
undergoing laparoscopic liver resection have a better survival
than predicted.13 Our current results indicate 2 possible expla-
nations to this: first, a reduced inflammatory response followed
by improved postoperative immune competence; second, a
reduced release of potentially oncogenic proteins as HMGB-
1. Randomized controlled trials with long-term follow-up are
needed to verify this.
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